NCT01083758View on ClinicalTrials.gov

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2012

Study Completion Date

October 31, 2012

Conditions
Scalp Psoriasis
Interventions
DRUG

LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)

Topical suspension applied once daily for up to 8 weeks

Trial Locations (6)

30327

Peachtree Dermatology Associates, PC, Atlanta

32174

Leavitt Medical Associates of Florida, Inc., Ormond Beach

32216

Leavitt Medical Associates of Florida, Inc., Jacksonville

47714

Deaconess Clinic, Evansville

68144

Skin Specialists, PC, Omaha

92123

Rady Children's Hospital San Diego, San Diego

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY

NCT01083758 - Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis | Biotech Hunter | Biotech Hunter